Novo Nordisk's obesity drug, amycretin, showed 13.1% weight loss in a trial, surpassing Tesla's market valuation.

Novo Nordisk's positive early-stage trial data for new obesity drug, amycretin, propelled its shares to rise and surpass Tesla's market valuation. The pill version of amycretin showed a 13.1% weight loss in participants after 12 weeks. With the launch of Wegovy in the U.S. in 2021, Novo Nordisk's market valuation reached $566 billion, solidifying its position as an obesity drug market leader.